SGI-110
Abstract Number: 679 Presentation Title: SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Abstract Number: 678 Presentation Title: Evaluation of oral bioavailability and intermittent dosing schedules for pharmacodynamic effects by SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA), in male cynomolgus monkeys
Abstract Number: 681 Presentation Title: SGI-110, a novel 5-aza-2’-deoxycytidine- containing dinucleotide, induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia (AML) cells
Abstract Number: 680 Presentation Title: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies
Sentiment: Buy